NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 862.7 DKK | -0.99% |
|
-0.76% | +23.58% |
| Apr. 18 | India's Biocon developing its own version of Wegovy, clinical trial likely next year | RE |
| Apr. 15 | More than 250 websites selling fake weight-loss drugs reported by anti-counterfeit firm | RE |
Presenter SpeechRichard Vosser (Analysts)Good morning, good afternoon to everyone. A warm welc...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
862.7
DKK
Average target price
904.2
DKK
Spread / Average Target
+4.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.58% | 554B | |
| +27.97% | 676B | |
| -7.02% | 349B | |
| +14.85% | 318B | |
| +6.25% | 291B | |
| +2.96% | 210B | |
| -0.41% | 204B | |
| -10.02% | 194B | |
| -11.81% | 144B | |
| -8.80% | 142B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Transcript : Novo Nordisk A/S Presents at JP Morgan EU Healthcare CEO Conference Calls Series 2022, Sep-14-2022 02
